Leerink upgraded Doximity (DOCS) to Outperform from Market Perform with a price target of $90, up from $60. While “admittedly late on this,” ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied promised bonuses and deferred grant awards worth millions of dollars.

Equities researchers at Leerink Partnrs boosted their Q2 2025 earnings estimates for shares of Twist Bioscience in a research ...

Leerink downgraded Hologic (HOLX) to Market Perform from Outperform with a price target of $75, down from $80, following the fiscal Q1 report.

Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (NasdaqGS:HOLX) from Outperform to Market Perform. Analyst Price Forecast Suggests 20.21% Upside As of ...

In a dramatic turnaround from bankruptcy court less than two years ago, Leerink Partners is now on the offensive and hiring ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of AbbVie in a research note issued to investors on Monday, February 3rd. Leerink ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (WBAG:ALGN) from Market Perform to Outperform. There are 1,519 funds or institutions reporting ...